for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Pfizer Inc.

PFE.N

Latest Trade

30.90USD

Change

-0.85(-2.68%)

Volume

12,966,441

Today's Range

30.68

 - 

31.73

52 Week Range

27.89

 - 

44.55

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
31.75
Open
30.80
Volume
12,966,441
3M AVG Volume
665.97
Today's High
31.73
Today's Low
30.68
52 Week High
44.55
52 Week Low
27.89
Shares Out (MIL)
5,547.64
Market Cap (MIL)
171,422.00
Forward P/E
--
Dividend (Yield %)
4.92

Next Event

Pfizer Inc Annual Shareholders Meeting

Latest Developments

More

S. Africa's Competition Commission Conditionally Approves Proposed Merger Whereby UpJohn Intends To Acquire Mylan

Alphamab Oncology Announces Clinical Supply Collaboration With Pfizer On Kn026 In Combination With Ibrance(R) (Palbociclib)

Shanghai Junshi Biosciences Says Toripalimab In Combination With Axitinib Granted Orphan-Drug Designation By US FDA

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Pfizer Inc.

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. Its brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra.

Contact Info

235 E 42ND ST

NEW YORK, NY

10017-5703

United States

+1.212.5732323

https://www.pfizer.com/

Executive Leadership

Albert Bourla

Chairman of the Board, Chief Executive Officer

John D. Young

Chief Business Officer, Group President

Frank A. D'Amelio

Chief Financial Officer, Executive Vice President - Business Operations and Global Supply

Angela Hwang

Group President, Pfizer Biopharmaceuticals Group

Dawn Rogers

Chief Human Resource Officer, Executive Vice President

Key Stats

2.50 mean rating - 16 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

52.5K

2018

53.6K

2019

51.8K

2020(E)

50.2K
EPS (USD)

2017

2.650

2018

3.000

2019

2.950

2020(E)

2.901
Price To Earnings (TTM)
11.01
Price To Sales (TTM)
3.31
Price To Book (MRQ)
2.71
Price To Cash Flow (TTM)
7.80
Total Debt To Equity (MRQ)
82.59
LT Debt To Equity (MRQ)
56.94
Return on Investment (TTM)
12.43
Return on Equity (TTM)
9.78

Latest News

Latest News

BRIEF-Alphamab Oncology Announces Clinical Supply Collaboration With Pfizer On Kn026 In Combination With Ibrance(R) (Palbociclib)

* ALPHAMAB ONCOLOGY ANNOUNCES CLINICAL SUPPLY COLLABORATION WITH PFIZER ON KN026 IN COMBINATION WITH IBRANCE(R) (PALBOCICLIB)

BRIEF-Alphamab Oncology Says Unit And Pfizer Enter Clinical Trial Agreement

* COLLABORATION WITH PFIZER ON KN026 IN COMBINATION WITH IBRANCE(PALBOCICLIB) IN HER2+ BREAST CANCER Source text for Eikon: Further company coverage:

Drugmakers Mylan, Pfizer delay merger due to coronavirus outbreak

Drugmaker Mylan NV's <MYL.O> merger with Pfizer Inc's <PFE.N> off-patent branded drug unit, Upjohn, will now close in the second half of this year, the companies said on Thursday, blaming the coronavirus pandemic for the delay.

Drugmakers Mylan, Pfizer delay merger due to coronavirus outbreak

Drugmaker Mylan NV's merger with Pfizer Inc's off-patent branded drug unit, Upjohn, would now close in the second half of 2020 due to the delays surrounding coronavirus, the companies said on Thursday.

BRIEF-Pfizer Inc Files For Pricing Of Notes Offering Of Up To $1.25 Billion

* PFIZER INC FILES FOR PRICING OF NOTES OFFERING OF UP TO $1.25 BILLION - SEC FILING Source text: (http://www.sec.gov/Archives/edgar/data/78003/000093041320000899/0000930413-20-000899-index.htm) Further company coverage:

U.S. drugmaker Pfizer pauses new studies due to coronavirus pandemic

Pfizer Inc said on Wednesday it was delaying patient recruitment in new and ongoing global trials for three weeks due to the coronavirus outbreak, as drugmakers look to ease the burden on healthcare facilities and on doctors treating coronavirus patients.

Pfizer pauses new studies due to coronavirus

Pfizer Inc said on Wednesday it was pausing patient recruitment in new and ongoing global studies for three weeks due to the coronavirus outbreak.

BRIEF-Pfizer pausing new clinical trial because of coronavirus outbreak

* Says pausing participant recruitment for three weeks for new and ongoing global interventional studies

BRIEF-Pfizer Announces Top-Line Results From Phase 3 Study Of 20-Valent Pneumococcal Conjugate Vaccine

* PFIZER ANNOUNCES TOP-LINE RESULTS FROM PHASE 3 STUDY OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS AGED 18 YEARS OR OLDER

Pfizer puts off investor day, reports two late-stage study results in advance

Pfizer Inc on Wednesday reported results from two late-stage studies ahead of schedule as it put off its March 31 investor day amid the coronavirus outbreak.

BRIEF-Pfizer Announces Positive Top-Line Results From Third Phase 3 Trial Of Abrocitinib

* PFIZER ANNOUNCES POSITIVE TOP-LINE RESULTS FROM THIRD PHASE 3 TRIAL OF ABROCITINIB FOR MODERATE TO SEVERE ATOPIC DERMATITIS, WHICH SHOWED IMPROVEMENTS IN SKIN CLEARANCE, DISEASE EXTENT AND SEVERITY, AND ITCH

Pfizer puts off investor day, reports two late-stage study results in advance

Pfizer Inc on Wednesday reported results from two late-stage studies ahead of schedule as it put off its March 31 investor day amid the coronavirus outbreak.

BRIEF-Pfizer Postpones Investor Day Scheduled For March 31, 2020 Due To Coronavirus Concerns

* PFIZER POSTPONES INVESTOR DAY SCHEDULED FOR MARCH 31, 2020 DUE TO CORONAVIRUS CONCERNS

BRIEF-Ideaya And Pfizer Enter Clinical Trial Collaboration And Supply Agreement

* IDEAYA AND PFIZER ENTER CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT TO EVALUATE CLINICAL COMBINATION OF IDE196 AND BINIMETINIB IN SOLID TUMORS HARBORING GNAQ OR GNA11 HOTSPOT MUTATIONS

BRIEF-Ideaya Biosciences Says Co Entered Into Clinical Trial Collaboration And Supply Agreement With Pfizer

* IDEAYA BIOSCIENCES - EFFECTIVE AS OF MARCH 11, ENTERED INTO CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT WITH PFIZER INC.

Pfizer, BioNTech to co-develop potential coronavirus vaccine

U.S. drugmaker Pfizer Inc <PFE.N> has signed a deal with Germany's BioNTech SE <22UAy.F> to co-develop a potential vaccine for the coronavirus using BioNTech's mRNA-based drug development platform, the companies said on Tuesday.

BRIEF-Pfizer and BioNTech to Co-Develop Potential COVID-19 Vaccine

* PFIZER SAYS CO, BIONTECH TO CO-DEVELOP POTENTIAL COVID-19 VACCINE

BRIEF-Pfizer Makes It Mandatory For All "Customer-Facing" Employees In U.S., Puerto Rico To Work Remotely - CNBC

* PFIZER MAKES IT MANDATORY FOR ALL “CUSTOMER-FACING” EMPLOYEES IN U.S. & PUERTO RICO TO WORK REMOTELY - CNBC Source text : [ID:https://cnb.cx/2U3khXF] Further company coverage:

BRIEF-Pfizer Says CEO Bourla's 2019 Total Compensation Was $17.9 Million

* PFIZER INC SAYS CEO A. BOURLA'S 2019 TOTAL COMPENSATION WAS $17.9 MILLION VERSUS $9.9 MILLION IN 2018 - SEC FILING

BRIEF-Pfizer Says Working To Advance Own Potential Antiviral Therapies And Is Engaged With BioNTech On A Potential MRNA Coronavirus Vaccine

* PFIZER - WORKING TO DEVELOP ANTIVIRAL THERAPIES TO HELP INFECTED PATIENTS FIGHT EMERGING VIRUS

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up